Edgar Filing: Synthetic Biologics, Inc. - Form 4

Synthetic B Form 4	iologics, Inc.									
January 12,	2015									
FORM			CECU					NT.	PPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							N OMB Number:	3235-0287	7	
Check ti if no lor subject Section Form 4 Form 5			SECUF	RITIES		WNERSHIP OF	Estimated burden hou response	urs per	5	
obligation may con <i>See</i> Inst 1(b).	ons ntinue. Section 17(a) of the l	Public U		ding Cor	npany Act	of 1935 or Section			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Ballantyne Charles Evan			2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [SYN]			C	5. Relationship of Reporting Person(s) to Issuer			
(1 +)	(First) (Middle)	•	C		[31]	(Check all applicable)			
(Last) C/O SYNT INC.,, 155 412	3. Date of Earliest Transaction (Month/Day/Year) 01/08/2015				Director 10% Owner XOfficer (give title Other (specify below) below) Chief Financial Officer					
(Street) 4.]				I. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check			
ROCKVIL	Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tal	ble I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	× ,			
Reminder: Re	port on a separate line	e for each cl	ass of sec	curities benef	Perso inforn requir	ns who res nation con red to resp nys a curre	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab			curities Acq ls, warrants			Beneficially Owned securities)	1		
1 77:1 0		d D	24 5	1	4	5 N 1			5 5 1	Π.

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securitie

Edgar Filing: Synthetic Biologics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		r)	(Instr. 3 and 4	4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Options	\$ 1.54	01/08/2015		А	200,000 (1)	01/08/2015(1)	01/08/2025	Common Stock	200,0

Reporting Owners

Reporting Owner Name / Address		Relationships						
, r · · · · · · · · · · · · · · · · · ·		irector	10% Owner	Officer	Other			
Ballantyne Charles Evan C/O SYNTHETIC BIOLOGICS 155 GIBBS STREET, SUITE 4 ROCKVILLE, MD 20850				Chief Financial Officer				
Signatures								
/s/ Charles Evan Ballantyne	01/12/201	5						
<u>**</u> Signature of Reporting	Date							

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options will vest quarterly on a pro rated basis over 36 consecutive months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.